Ultragenyx lays off 10% of workforce as FDA continues to stall gene therapy approval plans
Fuente:
FierceBiotech
Ultragenyx's employees were already braced for changes as the biopharma considered how to rebound from a pair of failed late-stage brittle bone disease trials.